logo
Plus   Neg
Share
Email

Stock Alert: DocuSign Up 8% After Q4 Results

Shares of DocuSign, Inc. (DOCU) gained nearly 8% on Friday morning trade. The company on Thursday had reported a fourth-quarter earnings and revenue that trumped Wall Street analyst estimates reflecting strong demand for its software.

The company's revenue and billings outlook also came in above expectations.

DOCU is currently trading at $74.06, up $5.38 or 7.83%, on the Nasdaq. The stock is up over 30% from last year.

The company reported a fourth-quarter loss of $47.4 million or $0.26 per share, compared with a loss of $66.2 million $0.40 per share last year.

Adjusted earnings were $0.12 cents per share, up from $0.06 per share in the year-ago period. Revenues rose to $274.9 million from $199.7 million in the year-ago period.

Analysts expected DocuSign earnings of $0.05 per share on sales of $266.5 million for the period.

For the first quarter, the company expects total revenues of $280 million to $284 million. Analysts currently expects revenue of $275.73 million.

Stocks rallied on Friday as Wall Street recovered some of the losses suffered in the previous session.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies. The U.S. Food and Drug Administration or FDA announced that Acella Pharmaceuticals, LLC recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency. The company is recalling 13 lots of NP Thyroid that are packaged in 100 count bottles in strengths of 30 mg, 60 mg, and 90 mg, with expiration dates between June 20, 2020, and December 20, 2020.
RELATED NEWS
Follow RTT